| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/11/2005 | WO2005072728A1 Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 08/11/2005 | WO2005072727A1 Eye drop composition |
| 08/11/2005 | WO2005072726A1 Compositions and methods of use of a-type procyanidins |
| 08/11/2005 | WO2005072725A1 The use of l-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease |
| 08/11/2005 | WO2005072724A1 Preventive and/or therapeutic agent for chronic cerebral circulatory failure |
| 08/11/2005 | WO2005072723A1 Pharmaceutical composition comprising hydroxylphenyl derivatives of rosmarinic acid for anticancer |
| 08/11/2005 | WO2005072722A2 Method of using punicic acid to enhance immune response and prevent metabolic disorders |
| 08/11/2005 | WO2005072721A1 Medicinal composition for preventing or treating neural disorders accompanying topical lowering in brian blood flow |
| 08/11/2005 | WO2005072720A1 Use of phenylbutyrate for treatment of spinal muscular atrophy |
| 08/11/2005 | WO2005072719A1 Medicinal acidic cannabinoids |
| 08/11/2005 | WO2005072718A1 Pharmaceutical compositions containing fermented whey |
| 08/11/2005 | WO2005072717A1 Biguanide preparation for internal use |
| 08/11/2005 | WO2005072716A1 Plaster enclosing packaging bag |
| 08/11/2005 | WO2005072715A1 Use of (s)-didesmethylsibutraminefor treating, preventing and managing a sleep disorder |
| 08/11/2005 | WO2005072714A1 Oral administration of r-albuterol against obesity |
| 08/11/2005 | WO2005072713A2 Cholinesterase inhibitors for treating inflammation |
| 08/11/2005 | WO2005072711A2 Method for producing sorbicillactone a |
| 08/11/2005 | WO2005072707A1 Nanoparticle-containing composition and process for producing the same |
| 08/11/2005 | WO2005072706A2 Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| 08/11/2005 | WO2005072705A1 Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| 08/11/2005 | WO2005072704A2 Method of treating acute rhinosinusitis |
| 08/11/2005 | WO2005072701A1 Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| 08/11/2005 | WO2005072691A1 Composition for inhibiting halitosis |
| 08/11/2005 | WO2005072681A2 Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain. |
| 08/11/2005 | WO2005072675A1 Package containing adhesive patch and method of inhibiting drug migration |
| 08/11/2005 | WO2005072528A1 Anticancer glycoside compounds |
| 08/11/2005 | WO2005072527A2 Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| 08/11/2005 | WO2005072505A2 Methods and compositions for the treatment of skin changes associated with aging and environmental damage |
| 08/11/2005 | WO2005072462A2 Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof |
| 08/11/2005 | WO2005072408A2 Treating a viral disorder |
| 08/11/2005 | WO2005072361A2 Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
| 08/11/2005 | WO2005072345A2 Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors |
| 08/11/2005 | WO2005072343A2 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use |
| 08/11/2005 | WO2005072274A2 Autoinducer-2 compounds as immunomodulatory agents |
| 08/11/2005 | WO2005072268A2 Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors |
| 08/11/2005 | WO2005072246A2 Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof |
| 08/11/2005 | WO2005072204A2 6,11-3c-bicyclic 8a-azalide derivatives |
| 08/11/2005 | WO2005072132A2 TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF |
| 08/11/2005 | WO2005072113A2 Compositions and methods of treatment for inflammatory diseases |
| 08/11/2005 | WO2005072091A2 Methods for inhibiting hiv and other viral infections by modulating ceramide metabolism |
| 08/11/2005 | WO2005072082A2 2-guanidinylimidazolidinedione compounds and methods of making and using thereof |
| 08/11/2005 | WO2005072079A2 Drug coating providing high drug loading and methods for providing the same |
| 08/11/2005 | WO2005072066A2 Preventive or therapeutic agent for diabetic maculopathy |
| 08/11/2005 | WO2005063219A3 Ibuprofen-containing soft gelatin capsules |
| 08/11/2005 | WO2005058898A3 Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| 08/11/2005 | WO2005058896A3 Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo[3.3.1]non-4-yl)benzamide hydrochloride hydrate |
| 08/11/2005 | WO2005058835A3 Methods of preparing aripiprazole crystalline forms |
| 08/11/2005 | WO2005057588A3 Granulated decontamination formulations |
| 08/11/2005 | WO2005055981A3 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 08/11/2005 | WO2005055973A3 Endoparasiticidal agents for topical application |
| 08/11/2005 | WO2005051940A3 Vitamin d receptor modulators |
| 08/11/2005 | WO2005051914A8 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/11/2005 | WO2005051372A3 Method of purifying pravastatin |
| 08/11/2005 | WO2005051302A3 Bicyclic inhibitors of mek and methods of use thereof |
| 08/11/2005 | WO2005051298A3 Novel phosphorus-containing thyromimetics |
| 08/11/2005 | WO2005047290A3 Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| 08/11/2005 | WO2005046588A3 Compounds, compositions, and methods |
| 08/11/2005 | WO2005044807A3 Benzoimidazole compounds |
| 08/11/2005 | WO2005041892A3 Purine receptor inhibition as a therapeutic strategy in spinal cord and brain |
| 08/11/2005 | WO2005041858A3 Mucin production inhibitor |
| 08/11/2005 | WO2005039639A3 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 08/11/2005 | WO2005039504A3 Compounds and methods for treating toll-like receptor 2-related diseases and conditions |
| 08/11/2005 | WO2005037245A3 A multiple route medication for the treatment of rhinitis and asthma |
| 08/11/2005 | WO2005036961A3 N-substituted azacycles |
| 08/11/2005 | WO2005034998A3 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 08/11/2005 | WO2005034908A3 A solid dosage form comprising a fibrate and a statin |
| 08/11/2005 | WO2005034856A3 Targeted drug-formaldehyde conjugates and methods of making and using the same |
| 08/11/2005 | WO2005032472A3 Pyrrolidine and piperidine derivatives as factor xa inhibitors |
| 08/11/2005 | WO2005030185A3 Method of inhibiting remnant lipoprotein production |
| 08/11/2005 | WO2005025536A9 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 08/11/2005 | WO2005025492A3 Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease |
| 08/11/2005 | WO2005023188A3 Compounds and methods |
| 08/11/2005 | WO2005020897A3 Compositions and methods for the treatment of disease associated with trp-p8 expression |
| 08/11/2005 | WO2005012243A3 Substituted indole-o-glucosides |
| 08/11/2005 | WO2005011651A3 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 08/11/2005 | WO2005011577A3 Methods for treating, preventing, or inhibiting injuries, cell membrane stabilization, and calcium mobilization using pseudopterosin compounds |
| 08/11/2005 | WO2005007635A3 Combretastatin derivatives with cytotoxic action |
| 08/11/2005 | WO2005000283A3 A method of treating degenerative disc disease |
| 08/11/2005 | WO2005000233A3 Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 08/11/2005 | WO2004112837A8 PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR |
| 08/11/2005 | WO2004110377A3 Porphyrins and metalloporphyrins for inhibiting heme iron uptake |
| 08/11/2005 | WO2004103276A3 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/11/2005 | WO2004093792A3 Compositions and methods for treating body malodor and fungal overgrowth in mammals |
| 08/11/2005 | WO2004089300A3 Sapphyrins and uses thereof |
| 08/11/2005 | WO2004078126A3 Compositions and methods with enhanced therapeutic activity |
| 08/11/2005 | WO2004056315A3 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 08/11/2005 | WO2004050842A3 Atm kinase compositions and methods |
| 08/11/2005 | WO2004014847A8 Mcp-1 receptor antagonists and method of use thereof |
| 08/11/2005 | WO2004012683A3 Novel druggable regions in set domain proteins and methods of using the same |
| 08/11/2005 | US20050176964 Nicotinamide derivatives useful as p38 inhibitors |
| 08/11/2005 | US20050176962 Aminating a -cyanophenylalanine derivative with hydroxylamine hydrochloride in the presence of sodium carbonate in alcoholic-aqueous solution at reflux temperature to a 3-amidino derivative; chemical intermediates as highly efficient urokinase inhibitors |
| 08/11/2005 | US20050176955 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors |
| 08/11/2005 | US20050176949 E.g., (2S, 3S, 4R, 5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoro-phenylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol, by aminating a 6-halopurine ribofuranose nucleoside in the presence of CaCO3 and an acid; adenosine A1 receptor agonist products are also claimed |
| 08/11/2005 | US20050176941 Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof |
| 08/11/2005 | US20050176940 Aptamers and antiaptamers |
| 08/11/2005 | US20050176938 Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate |
| 08/11/2005 | US20050176829 long-term continuous administration of low doses of thyroid hormones T3(triiodothyronine ); normalization of the cellular and serum levels of T3; side effect reduction |
| 08/11/2005 | US20050176828 Polyamine acylated with a hydrophobic acyl group, where acylation is by formation of either an amide or a sulfonamide linkage; antiproliferative agents; inhibition of cellular polyamine synthesis, even in the presence of exogenously supplied spermidine to inhibit cell growth and proliferation |
| 08/11/2005 | US20050176827 Metabolism, transportation of glucose and carbohydrates into muscle cells; mixture of 4-hydroxyisoleucine and amino acid |
| 08/11/2005 | US20050176826 Use of asc-1 inhibitors to treat neurological and psychiatric disorders |